T-Dxd in combination with immunotherapy (nivolumab) was evaluated in a phase 1b trial in patients affected by HER2-positive UC and is a new therapeutic approach that showed promising antitumour activity; the ADC induces immunogenic cell death that can enhance the recruitment of immune cells in the tumour microenvironment, activating the immune response [74]. Here, ERBB2 is linked to neoplasm.